Immunocore announces key appointments to management and Board
- Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp
- Dr. Roy S. Herbst appointed as a Non-Executive Director to the Board
OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 16 February 2021 – Immunocore Holdings plc (Nasdaq: IMCR), (or the “Company” or “Immunocore”), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the appointment of Ralph Torbay as its new Head of Commercial and the appointment of Dr. Roy S. Herbst as a member of its Board of Directors, effective January 28, 2021.